Navigation Links
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
Date:7/25/2013

MILWAUKEE, July 25, 2013 /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a private, emerging pharmaceutical company focused on developing a therapeutic platform for neuropsychiatric disorders, with an initial emphasis on creating drugs for the treatment of schizophrenia, announced today that Chad Beyer, Ph.D., MBA, has been appointed as President and Chief Executive Officer.

With nearly 20 years experience, Dr. Beyer's career encompasses research, discovery and the business development of medications intended for central nervous system (CNS) and neurological disorders.  As an entrepreneur, Dr. Beyer has founded a biotech consulting company and helped launch a specialty pharmaceutical company focused on developing treatments for acute pain conditions.

Klaus Veltinger, M.D., Ph.D., and chairman of Promentis' board of directors, stated, "We are thrilled to have Chad on board, he brings exceptional development experience to a well-established program that has already made considerable progress."   

Given Dr. Beyer's significant and extremely relevant experience in neuroscience, we're confident his abilities will have a direct and marked impact on Promentis' growth efforts."

For more than a decade, Dr. Beyer worked in the Discovery Neuroscience group at Wyeth Pharmaceuticals, where he held multiple positions of increasing responsibility, including Head of Neurochemistry.  During his time at Wyeth, he also led several drug discovery teams and managed a group of scientists that contributed to the submission of more than 30 INDs and generated supporting data for the commercialization and life-cycle management of Effexor® and Pristiq®, two of the company's blockbuster medications.

"Promentis is aggressively moving innovative science and novel treatment strategies closer to the millions of people suffering with CNS diseases," said Dr. Beyer.  "I am honored to join this unique team and to lead the company's drug discovery efforts closer to patients and their families."

Shortly after beginning his research career at the National Institutes of Health (NIH) in NIDA's Addiction Research Center, Dr. Beyer earned his Ph.D. in Pharmacology from Louisiana State University Medical Center and an MBA from the Rutgers School of Business.  He has authored more than 70 manuscripts, been granted three patents, is an editor of Next Generation Antidepressants, a psychiatry review book, and is co-founder of the journal Technology Transfer & Entrepreneurship.  Dr. Beyer also serves as an adjunct faculty member at Thomas Jefferson University where he teaches Bioventure Management.

About Promentis Pharmaceuticals, Inc:
Promentis Pharmaceuticals, Inc. was founded in 2007 and is a private, emerging pharmaceutical company focused on developing unique compounds aimed at modifying brain chemistry for the treatment of schizophrenia and other central nervous system disorders.  Support for Promentis' drug discovery and development programs, in part, is provided by recent grants from the National Institute of Mental Health (NIMH) and the Michael J. Fox Foundation.  Additional information can be found at www.promentispharma.com.

Media Contact:
Tiberend Strategic Advisors, Inc.
(212) 375-2694
Andrew Mielach
amielach@tiberend.com


'/>"/>
SOURCE Promentis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 The National University of ... data analytics company, signed a Memorandum of Understanding ... delivery in the region. Under ... Research and Technology (BIGHEART) at NUS and Holmusk ... related to healthcare IT and medical device development. ...
(Date:3/27/2017)... , March 27, 2017 ... specialty clinical-stage pharmaceutical company specializing in the development of ... public offering in the United States ... each ADS representing 40 ordinary shares of the ... In addition, Therapix has granted the underwriters a ...
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... METTLER TOLEDO Process Analytics is launching ... water and steam. , Chlorides and sulfates cause pitting and stress corrosion in ... and unplanned shutdowns. Monitoring these ions at low ppb levels has therefore been ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Columbus OH. Dr. ... as one of few medical professionals in the country to sit on the 2017 ... Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon ... and this procedure adds to SkyLex Advanced Surgical’s already comprehensive list of ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, Patten ... , The seed processing plant opened in Marshallville in 2006, and a bagging and ... allows opportunity for transition of Patten Seed operations to the Middle Georgia location from ...
(Date:3/28/2017)... ... ... Thank you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium in ... and offered an opportunity to collaborate and network with healthcare colleagues across the United ... gathered for a lively discussion on trends and issues that healthcare leaders will face ...
Breaking Medicine News(10 mins):